KLRS

Kalaris Therapeutics Inc

• TipRanks·9h ago

  Insider Move: Major Kalaris Therapeutics Stock Purchase Signals Growing Confidence

• PUBT·11h ago

  Samsara Opportunity Fund buys 244,300 Kalaris Therapeutics shares for $1.18 million

• TipRanks·05/14 19:48

  Starbucks upgraded, Doximity downgraded: Wall Street’s top analyst calls

• TipRanks·05/14 17:28

  Wedbush bullish on Kalaris Therapeutics, initiates with an Outperform

• Dow Jones·05/14 13:14

  Kalaris Therapeutics Price Target Announced at $17.00/Share by Wedbush

• Benzinga·05/14 13:04

  Wedbush Initiates Coverage On Kalaris Therapeutics with Outperform Rating, Announces Price Target of $17

• TipRanks·05/14 11:10

  Kalaris Therapeutics initiated with an Outperform at Wedbush

• Dow Jones·05/13 14:34

  Kalaris Therapeutics Price Target Cut to $25.00/Share From $26.00 by Citizens

• Dow Jones·05/13 14:34

  Kalaris Therapeutics Is Maintained at Market Outperform by Citizens

• Benzinga·05/13 14:24

  Citizens Maintains Market Outperform on Kalaris Therapeutics, Lowers Price Target to $25

• TipRanks·05/13 14:01

  Analysts Offer Insights on Healthcare Companies: Kalaris Therapeutics (KLRS), Zentalis Pharmaceuticals (ZNTL) and Bristol-Myers Squibb (BMY)

• TipRanks·05/13 09:56

  Kalaris Therapeutics price target lowered to $25 from $26 at Citizens

• TipRanks·05/12 21:50

  Analysts Are Bullish on Top Healthcare Stocks: Immunome (IMNM), Kalaris Therapeutics (KLRS)

• Seeking Alpha·05/12 17:23

  Kalaris Therapeutics, Inc. GAAP EPS of -$0.46

• TipRanks·05/12 16:14

  Kalaris Therapeutics reports Q1 EPS (46c), consensus (52c)